|
|
Article: Millennium's Velcade Granted Approval For Multiple Myeloma.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
National Editor
Bringing a new treatment option for patients with the fast-killing blood cancer multiple myeloma, Millennium Pharmaceuticals Inc. won FDA approval of the proteasome inhibitor Velcade (bortezomib) and plans to launch it next week.
The news, two months ahead of the FDA's deadline under the Prescription Drug User Fee Act, sent Millennium's stock (NASDAQ:MLNM) climbing up $1.90 Wednesday, or 15.2 percent, to close at $14.39.
"It was a great collaborative effort," said Kathy Giusti, president of the Multiple Myeloma Research Foundation (MMRF).
Velcade's approval comes only four and a half years from the first human dose, ...